Lantern Pharma (LTRN) Stock: Buy, Sell, or Hold?
LTRN - Lantern Pharma Inc. Common Stock
$1.09
-0.13 (-10.66%)
▼
5d:
-27.33%
30d:
-49.54%
90d:
-73.22%
WAIT
LOW Confidence
Analysis Updated: Sep 28, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When LTRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LTRN is down 27.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LTRN is down 27.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LTRN is currently trading at $1.09, which is considered oversold relative to its 30-day fair value range of $1.67 to $2.32.
Technical Outlook: Technically, LTRN is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: LTRN scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.50 (+1505.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LTRN is in a strong downtrend. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: LTRN scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.50 (+1505.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.67 -
$2.32
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.7%)
- BULLISH: Trading 1505.5% below Wall St target ($17.50)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.67 -
$2.32
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.96
Current Trend
Strong Downtrend
Technical data as of
Sep 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.54
Wall Street Target
$17.50
(+1505.5%)
Share & Embed Analysis
Last updated: September 29, 2026 8:44 AM ET
Data refreshes hourly during market hours. Next update: 9:44 AM
Data refreshes hourly during market hours. Next update: 9:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LTRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 44 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 72 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 60 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 40 SELL |
